| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db8a5c498dcdda99e818c6d50becd5cf |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485 |
| filingDate |
1973-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
1976-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
FR-2279394-A2 |
| titleOfInvention |
MEDICINE FOR THE TREATMENT OF CIRCULATORY CEREBRAL FAILURES |
| abstract |
Therapeutic compns. are new comprising dosage units contg. 2.5-30 mg. of vincamine, 1-25-15 mg of ascorbic acid and 15-250 mg of papaverine hydrochloride. A 3-ml injectable solution contg. 15 mg vincamine, 50 mg of papaverine hydrochloride, 60 mg ascorbic acid and 300 mg of propylene glycol stabilized with 0.003 ml of NaHSO3 solution and with water to 3 ml is specif claimed. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0227356-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2468373-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0227356-A3 |
| priorityDate |
1973-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |